Journal
HEALTH AFFAIRS
Volume 25, Issue 5, Pages 1281-1290Publisher
PROJECT HOPE
DOI: 10.1377/hlthaff.25.5.1281
Keywords
-
Ask authors/readers for more resources
Progress toward personalized medicine in the five years following the sequencing of the human genome has been slower than many expected. We focus on two potential factors that might be important in explaining this disappointing progress: the limitations of genetic prediction and the lack of appropriate economic incentives. Clinical application of DNA-based and other biomarkers is likely to succeed only on a case-by-case basis, depending on such factors as information content of the biomarker, accuracy of current assessment methods, and effectiveness of available interventions. Both strong intellectual property and value-based, flexible pricing systems will be important in making personalized medicine a reality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available